Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

NCT07594067 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT07594067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07594067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2026
Completion date
November 30, 2042
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, non-small cell lung cancer, pancreatic adenocarcinoma